Dataset Information

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

ABSTRACT: Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm whose severity and treatment complexity are attributed to the presence of bone marrow (BM) fibrosis and alterations of stroma impairing the production of normal blood cells. Despite the recently discovered mutations including the JAK2V617F mutation in about half of patients, the primitive event responsible for the clonal proliferation is still unknown. In the highly inflammatory context of PMF, the presence of fibrosis associated with a neoangiogenesis and an osteosclerosis concomitant to the myeloproliferation and to the increase number of circulating hematopoietic progenitors suggests that the crosstalk between hematopoietic and stromal cells is deregulated in the PMF BM microenvironmental niches. Within these niches, mesenchymal stromal cells (BM-MSC) play a hematopoietic supportive role in the production of growth factors and extracellular matrix which regulate the proliferation, differentiation, adhesion and migration of hematopoietic stem/progenitor cells. A transcriptome analysis of BM-MSC in PMF patients will help to characterize their molecular alterations and to understand their involvement in the hematopoietic stem/progenitor cell deregulation that features PMF.

SUBMITTER: Martinaud C

PROVIDER: S-EPMC4583614 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Martinaud Christophe C Desterke Christophe C Konopacki Johanna J Vannucchi Alessandro M AM Pieri Lisa L Guglielmelli Paola P Dupriez Brigitte B Ianotto Jean-Christophe JC Boutin Laetitia L Lataillade Jean-Jacques JJ Le Bousse-Kerdilès Marie-Caroline MC

Genomics data 20150429

Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm whose severity and treatment complexity are attributed to the presence of bone marrow (BM) fibrosis and alterations of stroma impairing the production of normal blood cells. Despite the recently discovered mutations including the JAK2V617F mutation in about half of patients, the primitive event responsible for the clonal proliferation is still unknown. In the highly inflammatory context of PMF, the presence of fibrosis associate ...[more]

PMID: 26484208

Similar Datasets

Project description:Autosomal dominant polycystic kidney disease (ADPKD) is a genetic ciliopathy disease characterized by progressive formation and enlargement of cysts in multiple organs. The kidneys are particularly affected and patients may eventually develop end-stage renal disease (ESRD). We hypothesize that bone marrow mesenchymal stromal cells (BMMSCs) are renotropic and may improve kidney function via anti-apoptotic, anti-fibrotic, and anti-inflammatory effects. In this study, we aim to assess the safety and tolerability of a BMMSC infusion in ADPKD patients.We performed a single-arm phase I clinical trial with a 12-month follow-up. This study enrolled six eligible ADPKD patients with an estimated glomerular filtration rate (eGFR) of 25-60 ml/min/1.73 m2. Patients received autologous cultured BMMSCs (2?×?106 cells/kg) through the cubital vein according to our infusion protocol. We investigated safety issues and kidney function during the follow-up visits, and compared the findings to baseline and 1 year prior to the intervention.There were no patients lost to follow-up. We observed no cell-related adverse events (AE) and serious adverse events (SAE) after 12 months of follow-up. The mean eGFR value of 33.8?±?5.3 ml/min/1.73 m2 1 year before cell infusion declined to 26.7?±?3.1 ml/min/1.73 m2 at baseline (P?=?0.03) and 25.8?±?6.2 ml/min/1.73 m2 at the 12-month follow-up visit (P?=?0.62). The mean serum creatinine (SCr) level of 2?±?0.3 mg/dl 1 year before the infusion increased to 2.5?±?0.4 mg/dl at baseline (P?=?0.04) and 2.5?±?0.6 mg/dl at the 12-month follow-up (P?=?0.96). This indicated significant changes between the differences of these two periods (12 months before infusion to baseline, and 12 months after infusion to baseline) in SCr (P?=?0.05), but not eGFR (P?=?0.09).This trial demonstrated the safety and tolerability of an intravenous transplantation of autologous BMMSCs. BMMSC efficacy in ADPKD patients should be investigated in a randomized placebo-controlled trial with a larger population, which we intend to perform.ClinicalTrials.gov, NCT02166489 . Registered on June 14, 2014.

Dataset Information

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Publications

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets